DK2006294T3 - MHC-molekyler bindende tumorassocierede peptider - Google Patents

MHC-molekyler bindende tumorassocierede peptider

Info

Publication number
DK2006294T3
DK2006294T3 DK08014304.3T DK08014304T DK2006294T3 DK 2006294 T3 DK2006294 T3 DK 2006294T3 DK 08014304 T DK08014304 T DK 08014304T DK 2006294 T3 DK2006294 T3 DK 2006294T3
Authority
DK
Denmark
Prior art keywords
cancer cells
cells
ile
val
incubated
Prior art date
Application number
DK08014304.3T
Other languages
Danish (da)
English (en)
Inventor
Toni Weinschenk
Hans-Georg Rammensee
Stefan Stevanovic
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Application granted granted Critical
Publication of DK2006294T3 publication Critical patent/DK2006294T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
DK08014304.3T 2002-05-29 2003-03-27 MHC-molekyler bindende tumorassocierede peptider DK2006294T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225144A DE10225144A1 (de) 2002-05-29 2002-05-29 An MHC-Moleküle bindende Tumor-assoziierte Peptide
EP03720376A EP1507795B1 (de) 2002-05-29 2003-03-27 An mhc-moleküle bindende tumor-assoziierte peptide

Publications (1)

Publication Number Publication Date
DK2006294T3 true DK2006294T3 (da) 2010-12-13

Family

ID=29557592

Family Applications (5)

Application Number Title Priority Date Filing Date
DK08014304.3T DK2006294T3 (da) 2002-05-29 2003-03-27 MHC-molekyler bindende tumorassocierede peptider
DK03720376T DK1507795T3 (da) 2002-05-29 2003-03-27 Tumorassocierede peptider, der binder til MHC-molekyler
DK08014305.0T DK2014673T3 (da) 2002-05-29 2003-03-27 Til MHC-molekyler bindende tumorassocierede peptider
DK06015805T DK1734048T3 (da) 2002-05-29 2003-03-27 Tumorassocierede peptider, der binder til MHC-molekyler
DK06015806T DK1734049T3 (da) 2002-05-29 2003-03-27 Tumorassocierede peptider, der binder til MHC-molekyler

Family Applications After (4)

Application Number Title Priority Date Filing Date
DK03720376T DK1507795T3 (da) 2002-05-29 2003-03-27 Tumorassocierede peptider, der binder til MHC-molekyler
DK08014305.0T DK2014673T3 (da) 2002-05-29 2003-03-27 Til MHC-molekyler bindende tumorassocierede peptider
DK06015805T DK1734048T3 (da) 2002-05-29 2003-03-27 Tumorassocierede peptider, der binder til MHC-molekyler
DK06015806T DK1734049T3 (da) 2002-05-29 2003-03-27 Tumorassocierede peptider, der binder til MHC-molekyler

Country Status (15)

Country Link
US (5) US7396904B2 (cg-RX-API-DMAC7.html)
EP (5) EP1734049B1 (cg-RX-API-DMAC7.html)
JP (5) JP4472520B2 (cg-RX-API-DMAC7.html)
AT (5) ATE478088T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003224001B2 (cg-RX-API-DMAC7.html)
CA (5) CA2487137C (cg-RX-API-DMAC7.html)
CY (5) CY1108507T1 (cg-RX-API-DMAC7.html)
DE (6) DE10225144A1 (cg-RX-API-DMAC7.html)
DK (5) DK2006294T3 (cg-RX-API-DMAC7.html)
ES (5) ES2317379T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20041108B1 (cg-RX-API-DMAC7.html)
PL (5) PL211158B1 (cg-RX-API-DMAC7.html)
PT (5) PT2006294E (cg-RX-API-DMAC7.html)
SI (5) SI1734048T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003102023A1 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
DE10225139A1 (de) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
PT2359841E (pt) * 2003-01-30 2015-02-10 Survac Aps Péptidos derivados de survivina e a sua utilização
DE10313819A1 (de) * 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US8637463B2 (en) 2003-12-01 2014-01-28 Meiji Dairies Corporation Peptide inhibiting angiotensin converting enzyme
JP2007515924A (ja) * 2003-12-15 2007-06-21 アウレリウム バイオファーマ インク. ビメンチン指向性診断法、および、多剤耐性を示す腫瘍性疾患の治療法
DE102004011503A1 (de) * 2004-01-28 2005-09-15 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung und Quantifizierung von tumor-assoziierten Peptiden
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
EP1642905B1 (en) * 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
HUE025636T2 (en) 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
WO2009129498A2 (en) * 2008-04-17 2009-10-22 Immuneregen Biosciences, Inc. Substance p and analogs thereof as a cancer immunogenic composition adjuvant
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
CN101451975B (zh) * 2008-12-29 2012-01-25 浙江大学 一种检测胃癌预后与分期血清蛋白质的方法
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
ES2900004T3 (es) 2013-08-05 2022-03-15 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC)
WO2015050259A1 (ja) * 2013-10-03 2015-04-09 大日本住友製薬株式会社 腫瘍抗原ペプチド
PL3068428T3 (pl) 2013-11-13 2023-03-13 Regents Of The University Of Minnesota Sposoby i kompozycje wariantów aneksyny ii
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
IL301919A (en) 2015-03-27 2023-06-01 Immatics Biotechnologies Gmbh Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201520558D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2019160383A1 (ko) * 2018-02-19 2019-08-22 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
KR102184377B1 (ko) 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
BR102018010523A2 (pt) * 2018-05-23 2020-04-28 Univ Estadual Campinas Unicamp peptídeo, composição farmacêutica compreendendo o mesmo e uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
US5739009A (en) * 1996-12-12 1998-04-14 Incyte Pharmaceuticals, Inc. Adipocyte-specific differentiation-related protein
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AU2001233957A1 (en) * 2000-02-24 2001-09-03 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression
WO2002050103A2 (en) * 2000-12-20 2002-06-27 Glaxosmithkline Biologicals S.A. Tumour-related antigens
US20030170719A1 (en) * 2000-12-28 2003-09-11 Akio Matsuda NF-kappa B activating gene
CA2444691A1 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2003048323A2 (en) * 2001-12-03 2003-06-12 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the development of rheumatoid arthritis

Also Published As

Publication number Publication date
JP5042302B2 (ja) 2012-10-03
PT1507795E (pt) 2008-12-26
AU2003224001A1 (en) 2003-12-19
AU2003224001B2 (en) 2010-03-11
US20050222390A1 (en) 2005-10-06
PL206306B1 (pl) 2010-07-30
SI1734049T1 (sl) 2009-02-28
US7666984B2 (en) 2010-02-23
ATE478088T1 (de) 2010-09-15
DE50310952D1 (de) 2009-01-29
ATE466872T1 (de) 2010-05-15
ES2317378T3 (es) 2009-04-16
JP2010099078A (ja) 2010-05-06
JP5042303B2 (ja) 2012-10-03
CA2736926A1 (en) 2003-12-11
JP2010099080A (ja) 2010-05-06
DK1507795T3 (da) 2008-12-08
DE50310882D1 (de) 2009-01-15
DK1734048T3 (da) 2009-02-23
EP2014673A1 (de) 2009-01-14
US20080051347A1 (en) 2008-02-28
EP1734049B1 (de) 2008-12-03
EP1734048B1 (de) 2008-12-17
JP5042300B2 (ja) 2012-10-03
US7396904B2 (en) 2008-07-08
AU2010200689A1 (en) 2010-03-18
EP1734049A1 (de) 2006-12-20
US8399613B2 (en) 2013-03-19
SI2014673T1 (sl) 2010-09-30
HRP20041108B1 (hr) 2013-11-08
DE50312701D1 (de) 2010-06-17
PL211157B1 (pl) 2012-04-30
DE10225144A1 (de) 2003-12-18
DK1734049T3 (da) 2009-01-19
CY1110723T1 (el) 2015-06-10
CA2487137A1 (en) 2003-12-11
EP2006294A1 (de) 2008-12-24
PL211159B1 (pl) 2012-04-30
US7763711B2 (en) 2010-07-27
SI1734048T1 (sl) 2009-02-28
CA2736921A1 (en) 2003-12-11
PT1734049E (pt) 2008-12-26
CA2736972C (en) 2014-08-05
PL373700A1 (en) 2005-09-05
CA2736974A1 (en) 2003-12-11
DE50310613D1 (de) 2008-11-20
JP2010088449A (ja) 2010-04-22
CY1108680T1 (el) 2014-04-09
PT2014673E (pt) 2010-08-04
CA2736972A1 (en) 2003-12-11
PT1734048E (pt) 2009-01-02
ATE410442T1 (de) 2008-10-15
PT2006294E (pt) 2010-11-12
WO2003102023A1 (de) 2003-12-11
US20080057077A1 (en) 2008-03-06
ES2317379T3 (es) 2009-04-16
CY1108673T1 (el) 2014-04-09
ES2314196T3 (es) 2009-03-16
SI1507795T1 (sl) 2009-04-30
HRP20041108A2 (en) 2005-10-31
CA2736974C (en) 2014-09-02
EP2006294B1 (de) 2010-08-18
JP2006511196A (ja) 2006-04-06
JP5042301B2 (ja) 2012-10-03
US20100183644A1 (en) 2010-07-22
EP2014673B1 (de) 2010-05-05
JP4472520B2 (ja) 2010-06-02
CA2736926C (en) 2015-11-17
US8536304B2 (en) 2013-09-17
CA2487137C (en) 2013-02-19
EP1507795B1 (de) 2008-10-08
JP2010099079A (ja) 2010-05-06
AU2010200689B2 (en) 2012-07-12
ES2350461T3 (es) 2011-01-24
ATE416188T1 (de) 2008-12-15
DE50313004D1 (de) 2010-09-30
CA2736921C (en) 2013-09-03
CY1111174T1 (el) 2015-06-11
CY1108507T1 (el) 2014-04-09
DK2014673T3 (da) 2010-08-30
US20100184211A1 (en) 2010-07-22
ES2348468T3 (es) 2010-12-07
SI2006294T1 (sl) 2010-11-30
ATE417859T1 (de) 2009-01-15
PL210356B1 (pl) 2012-01-31
EP1507795A1 (de) 2005-02-23
EP1734048A1 (de) 2006-12-20
PL211158B1 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
DE50310882D1 (de) An MHC-Moleküle bindende Tumor-assoziierte Peptide
AU2023285735B2 (en) Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
US20110142842A1 (en) Polypeptides
UA98295C2 (ru) Опухолево-ассоциированный пептид, который неспецифически связывается с молекулами ii класса лейкоцитарного антигена человека (hla)
AU2014407539A1 (en) Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
Schirmer et al. Transgenic antigen-specific, HLA-A* 02: 01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity
Bownds et al. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2. 1 binding affinity and stability in solution
WO2008007711A1 (en) Sart3-derived peptide useful in cancer vaccine therapy for hla-a3 supertype allele-positive prostate cancer patient
EP1667716B8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
JP2017081836A (ja) 細胞傷害性t細胞の作製方法
DE50013990D1 (de) Einem Peptid aus Antigen MUC-1 entsprechende DNS zur Auslösung einer Immunreaktion gegen Tumorzellen
JP7096397B2 (ja) がん特異的突然変異に対し抗原特異性を有するt細胞を単離する方法
Leet Personal Neoantigen Vaccines Induce Persistent Neoantigen-Specific Memory T Cell Responses and Epitope Spreading in High-Risk Melanoma Patients
JP2020143057A (ja) がん特異的突然変異に対し抗原特異性を有するt細胞受容体を単離する方法
Multhoff HSP70 peptide acting as a danger signal for Natural Killer (NK) cells